TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23159524

Group type: EXPERIMENTAL
Intervention: 4 mg BUP
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 16 mg BUP
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 21531237

Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring (3 times per week)
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Tailored behavioral self-management intervention administered via telephone by a nurse every other month
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Combination of home blood pressure monitoring and tailored behavioral self-management intervention
Number of subjects: 634

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 634
Study: 19704064

Group type: EXPERIMENTAL
Intervention: Six courses of paclitaxel 175 mg/m² every 3 weeks (maintenance)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Observation (control)
Number of subjects: 200
Study: 17075665

Group type: EXPERIMENTAL
Intervention: Electrode placement at the left mid-axillary line at the fourth and fifth intercostal spaces (CO2)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Recommended electrode placements (CO1 and CO3)
Number of subjects: 30
Study: 15246901

Group type: COMPARATOR
Intervention: Polymer-free Paclitaxel stents (0.2 to 3.1 microg paclitaxel/mm²)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Polymer-free Paclitaxel stents (0.7 to 3.1 microg/mm²)
Number of subjects: 326
Study: 11758844

Group type: EXPERIMENTAL
Intervention: Gentamicin 2.0-2.5 mg/kg twice daily
Number of subjects: 54

Group type: COMPARATOR
Intervention: Gentamicin 4.0-5.0 mg/kg once daily
Number of subjects: 54
Study: 9413851

Group type: EXPERIMENTAL
Intervention: Heparin-coated circuits (group H)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Uncoated circuits (group C)
Number of subjects: 24
Study: 8484654

Group type: EXPERIMENTAL
Intervention: Levobunolol
Number of subjects: 115

Group type: COMPARATOR
Intervention: Timolol
Number of subjects: 115
Study: 3610515

Group type: EXPERIMENTAL
Intervention: Topical benzydamine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 29040231

Group type: EXPERIMENTAL
Intervention: Continuous infusion through an OnQ pump
Number of subjects: 50

Group type: COMPARATOR
Intervention: Single-shot nerve block (SSB group)
Number of subjects: 50
Study: 27207739

Group type: EXPERIMENTAL
Intervention: CQ‐01 (a guar gum‐based hydrogel impregnated with peppermint oil, menthol, and methyl salicylate)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Gel control
Number of subjects: 74

Group type: COMPARATOR
Intervention: Gauze negative control
Number of subjects: 74
Study: 24887229

Group type: EXPERIMENTAL
Intervention: Need as a motivation for blood donation
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Safety concerns
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Fear of donating blood
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Active blood donors
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Occasional blood donors
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Rare blood donors
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Non-donors
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Attitudes towards intention to donate
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Indifference towards blood donation
Number of subjects: 800
Study: 22178630

Group type: EXPERIMENTAL
Intervention: Compressive fracture strength test
Number of subjects: 40

Group type: COMPARATOR
Intervention: Three point flexure test
Number of subjects: 40

Group type: COMPARATOR
Intervention: Biaxial flexure test
Number of subjects: 40

Group type: COMPARATOR
Intervention: Coefficient of Variation (CoV) values
Number of subjects: 40
Study: 20646375

Group type: EXPERIMENTAL
Intervention: Harmonic Focus (F)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Traditional technique (C)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 93
Study: 17640421

Group type: EXPERIMENTAL
Intervention: Tomato juice without vitamin C (L)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tomato juice with vitamin C (LC)
Number of subjects: 0
Study: 15219043

Group type: EXPERIMENTAL
Intervention: Sodium enoxaparin
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 2
Study: 11112678

Group type: EXPERIMENTAL
Intervention: Oral cefixime
Number of subjects: 200

Group type: COMPARATOR
Intervention: Intravenous antibiotics
Number of subjects: 200
Study: 9689265

Group type: EXPERIMENTAL
Intervention: 1.5% sevoflurane
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 2.5% sevoflurane
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1.5% and 2.5% sevoflurane
Number of subjects: 20
Study: 8270972

Group type: EXPERIMENTAL
Intervention: Transdermal clonidine
Number of subjects: 0
Study: 2511726

Group type: EXPERIMENTAL
Intervention: 0.5% halothane anaesthesia
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: neurolept anaesthesia
Number of subjects: 20
Study: 831435

Group type: EXPERIMENTAL
Intervention: Jejunoileal bypass operation
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control (unoperated)
Number of subjects: 138
Study: 31621668

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Group D) 1 μg/kg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Esmolol (Group E) 2 mg/kg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combination of dexmedetomidine and esmolol (Group DE) 0.5 μg/kg dexmedetomidine with 1 mg/kg esmolol
Number of subjects: 90
Study: 28344112

Group type: EXPERIMENTAL
Intervention: 0.5 mg semaglutide
Number of subjects: 1089

Group type: EXPERIMENTAL
Intervention: 1.0 mg semaglutide
Number of subjects: 1089

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 1089
Study: 25939908

Group type: EXPERIMENTAL
Intervention: CO2 insufflation (group A)
Number of subjects: 300

Group type: COMPARATOR
Intervention: No CO2 insufflation (group B)
Number of subjects: 300
Study: 22691110

Group type: EXPERIMENTAL
Intervention: Inhaled atropine sulfate via MicroDose Dry-Powder Inhaler (DPIA), 1.95 mg (5 doses × 0.4 mg per dose delivered over 12 min)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Intramuscular (IM) atropine via auto-injector (AUTO), 2 mg
Number of subjects: 17
Study: 21144780

Group type: EXPERIMENTAL
Intervention: Toltrazuril (T)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Diclazuril (D)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 120
Study: 18590586

Group type: EXPERIMENTAL
Intervention: Inulin (10 g/d) for 16 days
Number of subjects: 12
Study: 16483083

Group type: EXPERIMENTAL
Intervention: Community-based cleanliness campaign
Number of subjects: 0
Study: 14706720

Group type: EXPERIMENTAL
Intervention: Kava extract WS 1490
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 11230611

Group type: EXPERIMENTAL
Intervention: 1% permethrin creme rinse (1% PER)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: oral trimethoprim/sulfamethoxazole (TMP/SMX)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Combination of 1% PER and TMP/SMX
Number of subjects: 115
Study: 9149675

Group type: EXPERIMENTAL
Intervention: CO inhalation (1000 ppm for first 30 minutes, 100 ppm for last 30 minutes)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Vehicle (room air inhalation)
Number of subjects: 10
Study: 7957468

Group type: EXPERIMENTAL
Intervention: Uro-Vaxom (UV)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 3579364

Group type: EXPERIMENTAL
Intervention: Carbon monoxide (CO) exposure (100 ppm, COHb average = 3.8 +/- 0.1%)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Air exposure (COHb = 1.5 +/- 0.05%)
Number of subjects: 30
Study: 29477015

Group type: EXPERIMENTAL
Intervention: Sad mood induction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Positive mood induction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative emotion differentiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emotion regulation difficulties
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Positive emotion differentiation
Number of subjects: 0
Study: 27756884

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (ACT) in stage II patients with high E2F score
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (ACT) in stage II patients with low E2F score
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated patients with low E2F score
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: E2F score as a prognostic biomarker
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: E2F score as a predictive biomarker
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: E2F score in stage I patients
Number of subjects: 0
Study: 25539792

Group type: EXPERIMENTAL
Intervention: Pulmonary perfusion with oxygenated blood or Custodiol™ HTK solution
Number of subjects: 90

Group type: COMPARATOR
Intervention: No pulmonary perfusion
Number of subjects: 90
Study: 23945405

Group type: EXPERIMENTAL
Intervention: 100 mg/day soy isoflavone supplementation
Number of subjects: 182

Group type: COMPARATOR
Intervention: 500 mg calcium carbonate (Control)
Number of subjects: 182
Study: 20578658

Group type: EXPERIMENTAL
Intervention: CCLAD (computer-controlled local anesthetic delivery system)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional buccal/palatal injections
Number of subjects: 40
Study: 18396848

Group type: EXPERIMENTAL
Intervention: Training programme for early childhood educators and children
Number of subjects: 278

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 278
Study: 17240781

Group type: EXPERIMENTAL
Intervention: Treadmill exercise at 70% VO2max
Number of subjects: 8

Group type: COMPARATOR
Intervention: Treadmill exercise at 30% VO2max
Number of subjects: 8

Group type: COMPARATOR
Intervention: Treadmill exercise at 50% VO2max
Number of subjects: 8

Group type: COMPARATOR
Intervention: Resting experiment
Number of subjects: 8
Study: 14663900

Group type: EXPERIMENTAL
Intervention: Sorbilact infusion (twice a day for 4 days postoperatively)
Number of subjects: 12
Study: 10779832

Group type: EXPERIMENTAL
Intervention: Severe closed head injury (CHI) subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients in more demanding situations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controls tested in a random presentation
Number of subjects: 0
Study: 8657096

Group type: EXPERIMENTAL
Intervention: Persistent insufficient sleep (PIS)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Persistent insufficient sleep (PIS) without sleeping difficulties
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Persistent insufficient sleep (PIS) with concomitant sleep complaints
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Persistent insufficient sleep (PIS) without sleep complaints
Number of subjects: 600
Study: 1387972

Group type: EXPERIMENTAL
Intervention: Hepaccine‐B vaccine (3 micrograms) at schedules of 0, 2, 6, 12 months
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Hepaccine‐B vaccine (3 micrograms) at schedules of 0, 1, 6, 12 months
Number of subjects: 182

Group type: COMPARATOR
Intervention: Hepaccine‐B vaccine (3 micrograms) at schedule of 0, 1, 2, 9 months
Number of subjects: 182

Group type: COMPARATOR
Intervention: Hevac‐B Pasteur vaccine (5 micrograms) at schedule of 0, 1, 2, 9 months
Number of subjects: 182
Study: 3885084

Group type: EXPERIMENTAL
Intervention: Tripotassium dicitrato-bismuthate tablet
Number of subjects: 35

Group type: COMPARATOR
Intervention: Tripotassium dicitrato-bismuthate liquid
Number of subjects: 35
Study: 30100404

Group type: EXPERIMENTAL
Intervention: Laparoscopic anti-reflux surgery
Number of subjects: 58

Group type: COMPARATOR
Intervention: No surgery (control)
Number of subjects: 58
Study: 29927206

Group type: EXPERIMENTAL
Intervention: Soft silicone drains (Group A, n = 19)
Number of subjects: 38

Group type: COMPARATOR
Intervention: No soft silicone drains (Group B, n = 19)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Soft silicone drains (Group A)
Number of subjects: 38

Group type: COMPARATOR
Intervention: No soft silicone drains (Group B)
Number of subjects: 38
Study: 24712563

Group type: EXPERIMENTAL
Intervention: Synthetic human GIP infusion with sitagliptin (inhibition of dipeptidyl peptidase 4)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Synthetic human GIP infusion with placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Synthetic human GLP‐1 infusion with sitagliptin (inhibition of dipeptidyl peptidase 4)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Synthetic human GLP‐1 infusion with placebo
Number of subjects: 24
Study: 23039985

Group type: COMPARATOR
Intervention: All-milk protein milk replacer
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: High-glucose high-bicarbonate OAE (without glycine)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: High-glucose high-bicarbonate OAE (with glycine)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Low-glucose OAE containing acetate and propionate
Number of subjects: 6
Study: 20163842

Group type: EXPERIMENTAL
Intervention: Tadalafil 2.5 mg
Number of subjects: 1056

Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg
Number of subjects: 1056

Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg
Number of subjects: 1056

Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 1056

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1056
Study: 18391638

Group type: EXPERIMENTAL
Intervention: Exercise training (4 weeks duration)
Number of subjects: 34
Study: 17995906

Group type: EXPERIMENTAL
Intervention: Cognitive depletion condition (modified Stroop task)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control (color word) group
Number of subjects: 49
Study: 15571444

Group type: EXPERIMENTAL
Intervention: Quantitative group earned incentives for a 50% decrease in urine benzoylecgonine concentrations
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Qualitative group earned incentives for providing urines with concentrations <300 ng/ml
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group encouraged to abstain under the same schedule
Number of subjects: 42
Study: 11421506

Group type: EXPERIMENTAL
Intervention: Formoterol Turbuhaler 9 microg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Terbutaline Turbuhaler 0.5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo Turbuhaler
Number of subjects: 0
Study: 9389292

Group type: EXPERIMENTAL
Intervention: Antigen challenge (pollen antigens)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Buffer challenge (diluent)
Number of subjects: 5
Study: 7506239

Group type: EXPERIMENTAL
Intervention: 0.05% chlorhexidine gluconate solution irrigation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Saline irrigation
Number of subjects: 32
Study: 3030650

Group type: EXPERIMENTAL
Intervention: TFT plus one drop daily of rHu IFN-alpha 2 arg (30 million iu/ml)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: TFT plus rHu IFN-gamma (30 million iu/ml)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: TFT plus a mixture of alpha plus gamma (0.3 million iu/ml each)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: TFT plus a mixture of alpha plus gamma (1.5 million iu/ml each)
Number of subjects: 45

Group type: COMPARATOR
Intervention: High-titer gamma interferon
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Mixture of alpha plus gamma at a moderate titer (1.5 million iu/ml each)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Low-titer interferon mixture
Number of subjects: 45
Study: 31819304

Group type: EXPERIMENTAL
Intervention: Oral probiotics (2x1 starting from the third postoperative day for 30 days, followed by 1x1 for two weeks each month for one year)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (no probiotics)
Number of subjects: 78
Study: 28956773

Group type: EXPERIMENTAL
Intervention: Metoprolol (100±53 mg/d)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 25564551

Group type: EXPERIMENTAL
Intervention: Second-generation cryoballoon (CB2)
Number of subjects: 360

Group type: COMPARATOR
Intervention: First-generation cryoballoon (CB1)
Number of subjects: 360
Study: 23465535

Group type: EXPERIMENTAL
Intervention: Cefazolin plus clarithromycin
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Cefazolin plus erythromycin
Number of subjects: 102

Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 102
Study: 21977861

Group type: EXPERIMENTAL
Intervention: Shengjing Zhongzi Tang
Number of subjects: 70

Group type: COMPARATOR
Intervention: Wuzi Yanzong Wan
Number of subjects: 70
Study: 18522686

Group type: EXPERIMENTAL
Intervention: HMB supplementation (300 mg HMB/kg feed)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unsupplemented control
Number of subjects: 0
Study: 16467546

Group type: EXPERIMENTAL
Intervention: NXY-059
Number of subjects: 1699

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1699

Group type: EXPERIMENTAL
Intervention: NXY-059 with alteplase
Number of subjects: 1699
Study: 15333385

Group type: EXPERIMENTAL
Intervention: CABG with CPB
Number of subjects: 40

Group type: COMPARATOR
Intervention: CABG without CPB
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 11212481

Group type: EXPERIMENTAL
Intervention: Two drug regimens
Number of subjects: 210
Study: 9334150

Group type: EXPERIMENTAL
Intervention: Oncoprotein c-erbB-2 expression in breast carcinomas
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Coincidence of c-erbB-2 and tenascin expression
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Maximal damage of the basal membrane in intraductal carcinoma
Number of subjects: 64
Study: 8323358

Group type: EXPERIMENTAL
Intervention: multinutrient enriched milk
Number of subjects: 31

Group type: COMPARATOR
Intervention: standard formula
Number of subjects: 31
Study: 2942630

Group type: COMPARATOR
Intervention: Acetaminophen with codeine (650 mg plus 60 mg every 4 to 6 hours)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Diflunisal (1,000 mg initially then 500 mg twice a day)
Number of subjects: 35
Study: 31888765

Group type: EXPERIMENTAL
Intervention: Incentive spirometer therapy (IS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no IS therapy)
Number of subjects: 50
Study: 29712896

Group type: EXPERIMENTAL
Intervention: Daratumumab plus lenalidomide and dexamethasone (DRd)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lenalidomide and dexamethasone (Rd)
Number of subjects: 0
Study: 27428394

Group type: EXPERIMENTAL
Intervention: Single-view ultrasound
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Four-view ultrasound
Number of subjects: 260
Study: 24119064

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide gel with fluoride and potassium nitrate
Number of subjects: 20

Group type: COMPARATOR
Intervention: 10% carbamide peroxide gel without desensitizers
Number of subjects: 20
Study: 23062408

Group type: EXPERIMENTAL
Intervention: Xueshuantong Injection (175 mg/d)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 63
Study: 19881333

Group type: EXPERIMENTAL
Intervention: Concomitant or adjuvant temozolomide (TMZ) with whole-brain irradiation (WBI)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Whole-brain irradiation (WBI) alone
Number of subjects: 280
Study: 19450114

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with bare-metal stents (BMS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass grafting (CABG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with drug-eluting stents (DES)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: On-pump coronary artery bypass grafting (CABG)
Number of subjects: 0
Study: 16208674

Group type: EXPERIMENTAL
Intervention: Exercise + dietary weight loss
Number of subjects: 316

Group type: COMPARATOR
Intervention: Healthy lifestyle control
Number of subjects: 316
Study: 11489752

Group type: EXPERIMENTAL
Intervention: 15 mg of lycopene twice daily for 3 weeks
Number of subjects: 26
Study: 9703292

Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg day(-1) for 12 months
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 52
Study: 7978131

Group type: EXPERIMENTAL
Intervention: Belscope blade
Number of subjects: 20

Group type: COMPARATOR
Intervention: Macintosh blade
Number of subjects: 20
Study: 3288871

Group type: EXPERIMENTAL
Intervention: Prophylactic sclerotherapy (n = 68)
Number of subjects: 133

Group type: COMPARATOR
Intervention: No prophylaxis (Control group, n = 65)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Prophylactic sclerotherapy (n = 68) among patients with alcoholic and moderately decompensated cirrhosis (Child-Pugh group B)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Prophylactic sclerotherapy
Number of subjects: 133
Study: 31987958

Group type: EXPERIMENTAL
Intervention: Ultrahypofractionated radiation therapy
Number of subjects: 13384

Group type: EXPERIMENTAL
Intervention: Increasing dose per fraction in the experimental arm
Number of subjects: 13384

Group type: EXPERIMENTAL
Intervention: Biochemical control at doses above approximately 80 Gy
Number of subjects: 13384
Study: 29033152

Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine (LB)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Bupivacaine Hydrochloride (HCL)
Number of subjects: 107
Study: 26642974

Group type: EXPERIMENTAL
Intervention: rTMS (0.5 Hz) with figure-8 coil
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: rTMS (0.5 Hz) with round coil
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sham coil
Number of subjects: 11
Study: 24670297

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE)
Number of subjects: 583

Group type: EXPERIMENTAL
Intervention: CEE plus medroxyprogesterone acetate (CEE + MPA)
Number of subjects: 583
Study: 22990464

Group type: EXPERIMENTAL
Intervention: NaFeEDTA
Number of subjects: 16

Group type: COMPARATOR
Intervention: FeSO4
Number of subjects: 16

Group type: COMPARATOR
Intervention: NaFeEDTA vs FeSO4
Number of subjects: 16
Study: 20232750

Group type: EXPERIMENTAL
Intervention: Malaria vaccine development
Number of subjects: 300000000

Group type: COMPARATOR
Intervention: Combination of control measures (e.g., drugs, larvicides, clearing breeding sites)
Number of subjects: 300000000